Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) EPS (Basic) (2016 - 2025)

Ironwood Pharmaceuticals' EPS (Basic) history spans 16 years, with the latest figure at -$0.01 for Q4 2025.

  • For Q4 2025, EPS (Basic) fell 200.0% year-over-year to -$0.01; the TTM value through Dec 2025 reached $0.16, up 1700.0%, while the annual FY2025 figure was -$0.01, 200.0% down from the prior year.
  • EPS (Basic) for Q4 2025 was -$0.01 at Ironwood Pharmaceuticals, down from $0.25 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $2.42 in Q2 2021 and bottomed at -$6.84 in Q2 2023.
  • The 5-year median for EPS (Basic) is $0.2 (2022), against an average of -$0.09.
  • The largest annual shift saw EPS (Basic) crashed 2950.0% in 2023 before it surged 1600.0% in 2025.
  • A 5-year view of EPS (Basic) shows it stood at $0.25 in 2021, then rose by 28.0% to $0.32 in 2022, then plummeted by 103.12% to -$0.01 in 2023, then skyrocketed by 200.0% to $0.01 in 2024, then tumbled by 200.0% to -$0.01 in 2025.
  • Per Business Quant, the three most recent readings for IRWD's EPS (Basic) are -$0.01 (Q4 2025), $0.25 (Q3 2025), and $0.15 (Q2 2025).